FindTrial
Sign In

AL3818

DRUG6 trials

Sponsors

Advenchen Laboratories, LLC, Sarcoma Oncology Research Center, LLC, Advenchen Pharmaceuticals, LLC.

Conditions

Alveolar Soft Part SarcomaCervical CancerCervical CarcinomaEndometrial CancerEndometrial CarcinomaEndometrial NeoplasmsFallopian Tube CarcinomaGlioblastoma

Phase 1

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
TerminatedNCT02558348
Advenchen Laboratories, LLCCervical Cancer, Endometrial Cancer, Ovarian Cancer
Start: 2015-11-30End: 2017-05-30Updated: 2019-06-19
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
Active, not recruitingNCT04165330
Sarcoma Oncology Research Center, LLCNon Small Cell Lung Cancer, Small Cell Lung Cancer, Soft Tissue Sarcoma +1
Start: 2019-10-17End: 2028-03-31Target: 56Updated: 2025-02-24
A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers
Not yet recruitingNCT07811297
Advenchen Pharmaceuticals, LLC.Endometrial Neoplasms, Glioblastoma, Ovarian Neoplasms +1
Start: 2026-09-01End: 2031-09-01Target: 138Updated: 2026-09-10

Phase 3

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
NCT02584478
Advenchen Laboratories, LLCCervical Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma +2
Start: 2015-12-31End: 2024-12-31Updated: 2023-11-08
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
RecruitingNCT03016819
Advenchen Laboratories, LLCAlveolar Soft Part Sarcoma, Leiomyosarcoma, Soft-Tissue Sarcoma +1
Start: 2017-08-15End: 2028-12-01Target: 325Updated: 2026-02-25

Unknown Phase

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)
NCT05612191
Advenchen Laboratories, LLCGynecologic Cancer, Sarcoma,Soft Tissue
Updated: 2022-11-28

Related Papers

Phase 3 study (APROMISS) of catequentinib hydrochloride (AL3818) monotherapy in patients with advanced alveolar soft part sarcoma (ASPS).
Journal of Clinical Oncology2026-05-27
A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).
Journal of Clinical Oncology2025-05-281 citations
TP035/#1557 Phase 3 study assessing the efficacy of adding AL3818 (catequentinib dihydrochloride, anlotinib hydrochloride) to chemotherapies in subjects with platimum resistant and refractory ovarian carcinoma
2022-12-01
A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma.
Journal of Clinical Oncology2021-05-2025 citations
Safety and PK results from a phase Ib study of AL3818 (anlotinib) hydrochloride in subjects with ovarian, cervical, and endometrial cancers.
Journal of Clinical Oncology2017-05-208 citations